Key facts
- Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals.
- The acquisition is valued at approximately $10 billion.
- Vertex Pharmaceuticals will expand its portfolio into rare endocrine diseases.
- Crinetics Pharmaceuticals has assets including PALSONIFY and atumelnant.
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals in a deal valued at approximately $10 billion. This acquisition represents a significant expansion for Vertex into the field of rare endocrine diseases. The move is expected to enhance Vertex's existing drug portfolio by integrating Crinetics' promising assets. Among the key assets included in the deal are PALSONIFY and atumelnant, both of which are seen as valuable additions to Vertex's pipeline. The acquisition is anticipated to strengthen Vertex's position in specialized therapeutic markets and accelerate its growth in areas with high unmet medical needs. Further details regarding the integration of the two companies and the future development of the acquired assets are expected to be released following the completion of the transaction.